Compass Pathways (NASDAQ:CMPS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS) from a strong sell rating to a sell rating in a research note released on Sunday.

CMPS has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating on shares of Compass Pathways in a research note on Wednesday, August 5th. UBS Group set a $18.00 price target on shares of Compass Pathways in a report on Thursday, May 7th. Wells Fargo & Company assumed coverage on shares of Compass Pathways in a report on Monday, July 27th. They set an “equal weight” rating and a $13.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. Finally, Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price objective for the company in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Compass Pathways has a consensus rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Stock Up 1.3%

Shares of Compass Pathways stock opened at $13.90 on Friday. The stock has a 50-day moving average price of $12.72 and a 200 day moving average price of $9.68. The company has a market cap of $1.92 billion, a P/E ratio of -3.01 and a beta of 2.50. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. Compass Pathways has a 1 year low of $3.97 and a 1 year high of $15.40.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, analysts expect that Compass Pathways will post -1.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP lifted its stake in shares of Compass Pathways by 0.6% in the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after buying an additional 50,000 shares during the last quarter. Nantahala Capital Management LLC grew its stake in Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after buying an additional 1,350,698 shares during the last quarter. Millennium Management LLC grew its stake in Compass Pathways by 39.9% in the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after buying an additional 774,090 shares during the last quarter. Toronto Dominion Bank grew its stake in Compass Pathways by 152.9% in the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after buying an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC raised its holdings in Compass Pathways by 1.6% in the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after acquiring an additional 34,894 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.